
0:00
1:26:37
In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice.
Jaruska Naidoo, MD
Professor of Medical Oncology
Royal College of Surgeons
Consultant, Medical Oncologist at Beaumont Hospital
X: @DrJNaidoo
Instagram: jarushkanaidoo
LinkedIn: https://www.linkedin.com/in/jarushka-naidoo-127a3b97/
Jacob Sands, MD
Assistant Professor of Medicine, Harvard Medical School
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
X: @sands_jacob
Instagram: jacobsands
LinkedIn: https://www.linkedin.com/in/jacobsands/
Ferdinandos Skoulidis, MD, PhD
Professor, Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
Więcej odcinków z kanału "Lung Cancer Considered"



Nie przegap odcinka z kanału “Lung Cancer Considered”! Subskrybuj bezpłatnie w aplikacji GetPodcast.








